Pacific Biosciences is trading 5.6% down today at $1.36 as investors position ahead of its Q2 2026 earnings report scheduled for release this afternoon.
- The market is awaiting clarity on Revio system adoption and revenue growth trajectories amid ongoing losses.
- Analysts expect the company to report approximately $41 million in revenue and a $0.14 per-share loss.
- The stock's decline comes despite a generally positive backdrop for the broader biotech sector.